Drugs / Surovatamig
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07201558 | Dec 2025 → Jun 2028 expected | rheumatoid arthritis, systemic lupus erythematosus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT04594642 | Mar 2021 → Jun 2028 expected | follicular lymphoma, high grade B-cell lymphoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06564038 | Jan 2025 → Jun 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, large B-cell lymphoma, mantle cell lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06137118 | Dec 2023 → Nov 2026 expected | B-cell acute lymphoblastic leukemia | AstraZeneca | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07571746 | Mar 2026 → Apr 2028 expected | idiopathic membranous glomerulonephritis | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06526793 | Nov 2024 → Apr 2028 expected | follicular lymphoma, large B-cell lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07509151 | May 2026 → Aug 2031 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07215585 | Nov 2025 → Jun 2030 expected | large B-cell lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06549595 | Aug 2024 → Nov 2031 expected | follicular lymphoma | AstraZeneca | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07736950 Comparator | Jan 2027 → Jan 2035 expected | follicular lymphoma | Australasian Leukaemia and Lymphoma Group | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-12-04 | AstraZeneca | Results AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH astrazeneca.com ↗
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)-negative complete responses in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies |
| 2024-11-07 | AstraZeneca | Results AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024 astrazeneca.com ↗
Data will also reinforce the safety profile of AZD0486, with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) events effectively mitigated by the double step-up dosing schedule. |
| 2024-06-16 | AstraZeneca | Results Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial astrazeneca.com ↗
Results from the ongoing Phase I, dose-escalation trial of AZD0486, a novel CD19xCD3 T cell engager, showed durable responses in patients with heavily pretreated relapsed/refractory follicular lymphoma with a median follow up of 11 months. |
| 2023-11-29 | AstraZeneca | Results AstraZeneca advances scientific leadership in haematology at ASH 2023 astrazeneca.com ↗
Updated Phase I data for AstraZeneca’s CD19/CD3 T-cell engager, AZD0486, will further demonstrate the acceptable safety profile and high response rate of this treatment in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). |
| 2023-05-16 | AstraZeneca | Results AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023 astrazeneca.com ↗
Interim clinical data will show promise of AZD0486, a novel T-cell engager for patients with relapsed or refractory follicular lymphoma |
| 2022-11-30 | AstraZeneca | Results AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022 astrazeneca.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Surovatamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07736950 ↗ |
| Known as | AZD0486 | “Surovatamig (AZD0486) monotherapy” NCT06526793 ↗ |
| Known as | TNB-486 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068301 ↗ |
| Action | Deplete | “leading to T cell-mediated cytotoxicity of malignant B cells” NCT04594642 ↗ |
| Modality | Protein / enzyme biologic | “Surovatamig is a bispecific T-cell engager administered subcutaneously.” NCT07201558 ↗ |
| Route | Intravenous | “administered intravenously” NCT04594642 ↗ |
| Target | CD19 | “novel CD19 × CD3 bispecific T-cell engager” NCT07736950 ↗ |